Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 15:10:745-752.
doi: 10.2147/JHC.S406902. eCollection 2023.

Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver

Jyotsna Gummadi  1 , Xin Wang  2 , Changqing Xie  2   3
Affiliations
Review

Current Advances in the Treatment of Fibrolamellar Carcinoma of Liver

Jyotsna Gummadi et al. J Hepatocell Carcinoma. .

Abstract

Fibrolamellar carcinoma (FLC) of the liver is a rare type of liver cancer that is prevalent in children and young adults, often less than 40 years old. The etiology is unclear. It presents without underlying liver disease with distinctive histological features such as fibrous collagen bands surrounding the tumor cells. Fusion protein DNAJB1-PRKACA is found in most of the cases. The prognosis of FLC is poor. Even though curative treatment option is surgery for a certain patient population, other treatment modalities including radiation, chemotherapy are currently being used without significant improvement of overall survival. Recently, targeted therapy and immunotherapy have been studied which may provide survival advantage in the future. This review sought to compile data from clinical trials and case reports/series to outline the current state of FLC treatment.

Keywords: fibrolamellar carcinoma of liver; immunotherapy; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91:168–186. doi:10.1001/archpedi.1956.02060020170015 - DOI - PubMed
    1. Limaiem F, Bouhamed M, Sahraoui G, et al. Hepatocellular carcinoma: a clinicopathological study of 64 cases. Pan Afr Med J. 2017;27:41. doi:10.11604/pamj.2017.27.41.9584 - DOI - PMC - PubMed
    1. Eggert T, McGlynn KA, Duffy A, et al. Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut. 2013;62:1667–1668. doi:10.1136/gutjnl-2013-305164 - DOI - PMC - PubMed
    1. Polychronidis G, Feng J, Murtha-Lemekhova A, et al. Factors influencing overall survival for patients with fibrolamellar hepatocellular carcinoma: analysis of the surveillance, epidemiology, and end results database. Int J Gen Med. 2022;15:393–406. doi:10.2147/IJGM.S338066 - DOI - PMC - PubMed
    1. Ramai D, Ofosu A, Lai JK, et al. Fibrolamellar hepatocellular carcinoma: a population-based observational study. Dig Dis Sci. 2021;66(1):308–314. doi:10.1007/s10620-020-06135-3 - DOI - PubMed